Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | PDXK | O00764 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ginkgotoxin SCHEMBL9127650 | 0.86 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Ginkgotoxin SCHEMBL29462283 | 0.86 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL18461165 | 0.85 | HPGD (0.69) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL11451323 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Ginkgotoxin SCHEMBL1848430 | 0.85 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL16681933 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL2322958 | 0.83 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30267871 | 0.83 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL3506 | 0.83 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30877002 | 0.83 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102952067-A | Pyridoxal derivative for pegylation modification of N terminal of protein and preparation method and application thereof | SUZHOU SINOCOMPOUND TECHNOLOGY CO LTD | 2013-03-06 | — | — | CN | claimed |
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2017037566-A1 | COMPOUND, COMPOSITION AND USES THEREOF | RAO M SURYA (IN) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017017585-A1 | COMPOUND, COMPOSITION AND USES THEREOF | MOHAN M ALAPATI (IN) | 2017-02-02 | — | — | WO | disclosed |
| US-20160332950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT | ALAPATI MOHAN MURALI (IN) | 2016-11-17 | — | — | US | disclosed |
| WO-2016181199-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT | MOHAN M ALAPATI (IN) | 2016-11-17 | — | — | WO | disclosed |
| US-9475747-B1 | Compositions and methods for the treatment of urea cycle disorders and gout | ALAPATI MOHAN MURALI (IN) | 2016-10-25 | — | — | US | disclosed |
| WO-2016046672-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DIABETES | MOHAN M ALAPATI (IN) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046669-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION AND NEUROLOGICAL DISEASES | MOHAN M ALAPATI (IN) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046674-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN | MOHAN M ALAPATI (IN) | 2016-03-31 | — | — | WO | disclosed |
| WO-2014203198-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND RENAL COMPLICATIONS | KANDULA MAHESH (IN) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014174425-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORTHOSTASIS AND NEUROLOGICAL DISEASES | KANDULA MAHESH (IN) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014122621-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC CONDITIONS AND NEUROMUSCULAR DISEASES | KANDULA MAHESH (IN) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014087367-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND ITS ASSOCIATED COMPLICATIONS | KANDULA MAHESH (IN) | 2014-06-12 | — | — | WO | disclosed |
| CN-102952067-A | Pyridoxal derivative for pegylation modification of N terminal of protein and preparation method and application thereof | SUZHOU SINOCOMPOUND TECHNOLOGY CO LTD | 2013-03-06 | — | — | CN | disclosed |
| EP-1037646-A1 | GINKGO BILOBA LEAF EXTRACTS WITH A REDUCED 4'-O-METHYLPYRIDOXINE AND BIFLAVONE CONTENT | Dr. Willmar Schwabe GmbH & Co. (DE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999032129-A1 | GINKGO BILOBA LEAF EXTRACTS WITH A REDUCED 4'-O-METHYLPYRIDOXINE AND BIFLAVONE CONTENT | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1999-07-01 | — | — | WO | disclosed |
| US-4212976-A | ANTIARTHRITIC AGENTS | MERCK & CO., INC. (US) | 1980-07-15 | — | — | US | disclosed |
| US-4057637-A | RHEUMATOID ARTHRITIS | MERCK & CO., INC. (US) | 1977-11-08 | — | — | US | disclosed |
| US-3971797-A | ANTIARTHRITIC | MERCK & CO., INC. (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT | SLC14A1, UMPS, UGT1A3 | KDM4E 3071/4885ALDH1A1 1034/4885HPGD 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.